Human Genome Epidemiology Literature Finder
Records 1 - 26 (of 26 Records) |
Query Trace: Neutropenia and CYP3A4[original query] |
---|
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004 Jan 103 (1): 67-72. Kishi Shinji, Yang Wenjian, Boureau Benoit, Morand Stanislas, Das Soma, Chen Peixian, Cook Edwin H, Rosner Gary L, Schuetz Erin, Pui Ching-Hon, Relling Mary |
Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clinical pharmacology and therapeutics 2006 Jun 79 (6): 570-80. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer J |
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenetics and genomics 2007 Jun 17 (6): 431-45. Nakajima Miki, Komagata Sayaka, Fujiki Yuto, Kanada Yoshihiro, Ebi Hiromichi, Itoh Kuniaki, Mukai Hirofumi, Yokoi Tsuyoshi, Minami Hirono |
A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006 Nov 1 (9): 972-8. Pillot Giancarlo A, Read William L, Hennenfent Kristin L, Marsh Sharon, Gao Feng, Viswanathan Avinash, Cummings Kristopher, McLeod Howard L, Govindan Ramaswa |
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer chemotherapy and pharmacology 2008 Aug 62 (3): 529-37. Sai Kimie, Saito Yoshiro, Fukushima-Uesaka Hiromi, Kurose Koichi, Kaniwa Nahoko, Kamatani Naoyuki, Shirao Kuniaki, Yamamoto Noboru, Hamaguchi Tetsuya, Kunitoh Hideo, Ohe Yuichiro, Tamura Tomohide, Yamada Yasuhide, Minami Hironobu, Ohtsu Atsushi, Yoshida Teruhiko, Saijo Nagahiro, Sawada Jun-ic |
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer science 2008 May 99 (5): 967-72. Kiyotani Kazuma, Mushiroda Taisei, Kubo Michiaki, Zembutsu Hitoshi, Sugiyama Yuichi, Nakamura Yusu |
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. Journal of human genetics 2009 Oct 54 (10): 564-71. Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos |
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jul 27 (21): 3540-6. Gandara David R, Kawaguchi Tomoya, Crowley John, Moon James, Furuse Kiyoyuki, Kawahara Masaaki, Teramukai Satoshi, Ohe Yuichiro, Kubota Kaoru, Williamson Stephen K, Gautschi Oliver, Lenz Heinz Josef, McLeod Howard L, Lara Primo N, Coltman Charles Arthur, Fukuoka Masahiro, Saijo Nagahiro, Fukushima Masanori, Mack Philip |
Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clinica chimica acta; international journal of clinical chemistry 2009 Jun 404 (2): 160-5. Tsai Shih-Meng, Lin Chiou-Ya, Wu Szu-Hsien, Hou Linda Ann, Ma Hsu, Tsai Li-Yu, Hou Ming-Fe |
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 16 (2): 736-42. van der Bol Jessica M, Mathijssen Ron H J, Creemers Geert-Jan M, Planting André S Th, Loos Walter J, Wiemer Erik A C, Friberg Lena E, Verweij Jaap, Sparreboom Alex, de Jong Floris |
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European journal of clinical pharmacology 2011 Jul 67 (7): 693-700. Bergmann Troels K, Gréen Henrik, Brasch-Andersen Charlotte, Mirza Mansoor R, Herrstedt Jørn, Hølund Berit, du Bois Andreas, Damkier Per, Vach Werner, Brosen Kim, Peterson Cu |
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. Journal of cancer research and clinical oncology 2013 Mar 139 (3): 419-27. Tang Nelson L S, Liao Chen Di, Wang Xingyan, Mo Frankie K F, Chan Vicky T C, Ng Rita, Pang Elizabeth, Suen Joyce J S, Woo Jean, Yeo Winn |
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene 2014 Jun 543 (1): 69-75. Tulsyan Sonam, Chaturvedi Pankaj, Singh Abhishek Kumar, Agarwal Gaurav, Lal Punita, Agrawal Sushma, Mittal Rama Devi, Mittal Balr |
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC pharmacology & toxicology 2015 16 2. Lambrechts Sandrina, Lambrechts Diether, Despierre Evelyn, Van Nieuwenhuysen Els, Smeets Dominiek, Debruyne Philip R, Renard Vincent, Vroman Philippe, Luyten Daisy, Neven Patrick, Amant Frédéric, Leunen Karin, Vergote Ignace, |
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. British journal of clinical pharmacology 2018 Mar . Riera Pau, Salazar Juliana, Virgili Anna C, Tobeña María, Sebio Ana, Gallano Pía, Barnadas Agustí, Páez Dav |
Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Frontiers in pharmacology 2019 10 206. Lavanderos María A, Cayún Juan P, Roco Ángela, Sandoval Christopher, Cerpa Leslie, Rubilar Juan C, Cerro Roberto, Molina-Mellico Sebastián, Celedón Cesar, Cerda Berta, García-Martín Elena, Agúndez José A G, Acevedo Cristián, Peña Karina, Cáceres Dante D, Varela Nelson M, Quiñones Luis |
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 2020 Jan . Belderbos Bodine P S, de With Mirjam, Singh Rajbir K, Agema Bram C, El Bouazzaoui Samira, Oomen-de Hoop Esther, de Wit Ronald, van Schaik Ron H N, Mathijssen Ron H J, Bins Sand |
Pharmacogenetics-Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort. Frontiers in pharmacology 2021 3 12 602676. Martinez Matias F, Alveal Enzo, Soto Tomas G, Bustamante Eva I, Ávila Fernanda, Bangdiwala Shrikant I, Flores Ivonne, Monterrosa Claudia, Morales Ricardo, Varela Nelson M, Fohner Alison E, Quiñones Luis |
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? Chemico-biological interactions 2022 Jul 364 110042. Sangüesa Estela, Cirujeda Christine, Concha Julia, Padilla Pedro Pablo, García Cristina Belén, Ribate María Pil |
Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report. Frontiers in oncology 2022 2 11 809527. Powell Nicholas R, Shugg Tyler, Ly Reynold C, Albany Costantine, Radovich Milan, Schneider Bryan P, Skaar Todd |
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 9 167 115479. Elena Peruzzi, Lorenzo Gerratana, Marcella Montico, Bianca Posocco, Serena Corsetti, Michele Bartoletti, Sara Gagno, Marco Orleni, Elena De Mattia, Massimo Baraldo, Erika Cecchin, Fabio Puglisi, Giuseppe Toffoli, Rossana Ronca |
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy. Cancers 2023 3 15 (5): . Urtasun Andrea, Olivera Gladys G, Sendra Luis, Aliño Salvador F, Berlanga Pablo, Gargallo Pablo, Hervás David, Balaguer Julia, Juan-Ribelles Antonio, Andrés María Del Mar, Cañete Adela, Herrero María Jo |
Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. Pharmacogenomics 2024 8 1-9. Chong Wang, Mary Hwang, Brandon Paulson, Doreen Mhandire, Sadat Ozair, Tracey L O'Connor, Shipra Gandhi, Kristopher M Attwood, Daniel L Hertz, Andrew Kl Go |
- Page last reviewed:Feb 1, 2024
- Content source: